← Back to Search

Imaging Techniques for Multiple Sclerosis

Phase 2

Waitlist Available

Led By Burcu Zeydan, MD

Research Sponsored by Mayo Clinic

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline

Awards & highlights

No Placebo-Only Group

Summary

This trial tests if MRI + PET/CT scans can help diagnose MS & measure brain inflammation related to it.

Who is the study for?

This trial is for individuals with Multiple Sclerosis (MS) who are already part of certain MS studies or clinics, and healthy controls without inflammatory brain diseases. Participants must be able to lie still for imaging procedures and give consent. Pregnant or breastfeeding women, recent steroid users, and those with MRI safety risks like pacemakers can't join.

What is being tested?

The study is testing the effectiveness of combining MRI scans with PET/CT imaging using C-11 ER176 Radiotracer and C11 Pittsburgh Compound B to measure brain inflammation in people with MS.

What are the potential side effects?

While not explicitly listed, potential side effects may include discomfort from lying still during imaging, allergic reactions to radiotracers, and exposure to radiation from PET/CT scans.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Uptake of C-11 ER176 Radiotracer

Uptake of C-11 Pittsburgh compound-B (PiB) in white matter myelin

Secondary study objectives

Number of subjects with adverse events

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Group I: Multiple Sclerosis GroupExperimental Treatment4 Interventions

Subjects with current diagnosis of Multiple Sclerosis or an InflammatoryDemyelinating Disease of the Central Nervous System will have a PET/CT scan with radiotracer drug C-11 PIB \& C-11 ER176

Group II: Healthy Control GroupExperimental Treatment4 Interventions

Subjects without inflammatory-demyelinating diseases of the central nervous system

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

PET/CT scan

2013

Completed Phase 1

~340

MRI

2009